Johnson & Johnson Signs a Manufacturing Agreement with the Catalent to Bolster the Capacity of COVID-19 Vaccine in the US
Shots:
- The alliance includes joint investment and tech transfer to accelerate rapid scale-up of segregated manufacturing capacity over the coming months for supporting J&J’s vaccine candidates
- Catalent will accelerate the availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington and plans to hire ~300 additional employees for the program initiating in Jul’2020 to support 24×7 manufacturing schedules by Jan’2021
- Catalent’s 875-000 square-foot Bloomington facility has expertise in drug substance development and manufacturing and the scale-up would utilize high-speed machines for vial filling and carton loading- Additionally- on Apr 27- 2020- J&J collaborated with Emergent to support manufacturing of its vaccine candidate
Click here to read full press release/ article | Ref: Catalent | Image: WSJ
Related News: Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of its Vaccine Against COVID-19
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
